Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease

Next Previous
X
Search
Trial Profile

An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonlicromanol (Primary)
  • Indications Leber's hereditary optic atrophy; Leigh disease; MELAS syndrome; Mitochondrial disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KHENERGY
  • Sponsors Khondrion

    • Most Recent Events

    • 31 Jul 2018 According to a Khondrion media release, the company has received a grant of EUR 2.3M from the EU Horizon 2020 SME instrument program, which will be used for the execution of this clinical trial.
    • 30 Jul 2018 Results (n=20) published in the Clinical Pharmacology and Therapeutics.
    • 22 Feb 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top